Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border
- PMID: 26928448
- PMCID: PMC4772585
- DOI: 10.1186/s12936-016-1181-1
Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border
Abstract
Background: A three-day course of chloroquine remains a standard treatment of Plasmodium vivax infection in Thailand with satisfactory clinical efficacy and tolerability although a continuous decline in in vitro parasite sensitivity has been reported. Information on the pharmacokinetics of chloroquine and its active metabolite desethylchloroquine are required for optimization of treatment to attain therapeutic exposure and thus prevent drug resistance development.
Methods: The study was conducted at Mae Tao Clinic for migrant worker, Tak province, Thailand. Blood samples were collected from a total of 75 (8 Thais and 67 Burmeses; 36 males and 39 females; aged 17-52 years) patients with mono-infection with P. vivax malaria [median (95 % CI) admission parasitaemia 4898 (1206-29,480)/µL] following treatment with a three-day course of chloroquine (25 mg/kg body weight chloroquine phosphate over 3 days). Whole blood concentrations of chloroquine and desethylchloroquine were measured using high performance liquid chromatography with UV detection. Concentration-time profiles of both compounds were analysed using a population-based pharmacokinetic approach.
Results: All patients showed satisfactory response to standard treatment with a three-day course of chloroquine with 100 % cure rate within the follow-up period of 42 days. Neither recurrence of P. vivax parasitaemia nor appearance of P. falciparum occurred. A total of 1045 observations from 75 participants were included in the pharmacokinetic analysis. Chloroquine disposition was most adequately described by the two-compartment model with one transit compartment absorption model into the central compartment and a first-order transformation of chloroquine into desethylchloroquine with an additional peripheral compartment added to desethylchloroquine. First-order elimination from the central compartment of chloroquine and desethylchloroquine was assumed. The model exhibited a strong predictive ability and the pharmacokinetic parameters were estimated with adequate precision.
Conclusion: The developed population-based pharmacokinetic model could be applied for future prediction of optimal dosage regimen of chloroquine in patients with P. vivax infection.
Figures
Similar articles
-
Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010.Malar J. 2011 Feb 16;10:44. doi: 10.1186/1475-2875-10-44. Malar J. 2011. PMID: 21324161 Free PMC article.
-
Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia.Malar J. 2008 Oct 29;7:220. doi: 10.1186/1475-2875-7-220. Malar J. 2008. PMID: 18959774 Free PMC article.
-
In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010.J Vector Borne Dis. 2011 Dec;48(4):190-6. J Vector Borne Dis. 2011. PMID: 22297279
-
[Research progress on Plasmodium vivax chloroquine resistance].Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2014 Jun;26(3):326-31. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2014. PMID: 25345166 Review. Chinese.
-
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance.Curr Opin Infect Dis. 2009 Oct;22(5):430-5. doi: 10.1097/QCO.0b013e32832f14c1. Curr Opin Infect Dis. 2009. PMID: 19571748 Review.
Cited by
-
Anti-malarial drug effects on parasite dynamics in vivax malaria.Malar J. 2021 Mar 21;20(1):161. doi: 10.1186/s12936-021-03700-7. Malar J. 2021. PMID: 33743731 Free PMC article. Review.
-
COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.PLoS Med. 2020 Sep 3;17(9):e1003252. doi: 10.1371/journal.pmed.1003252. eCollection 2020 Sep. PLoS Med. 2020. PMID: 32881895 Free PMC article.
-
Outcomes of the Health Insurance Card Scheme on Migrants' Use of Health Services in Ranong Province, Thailand.Int J Environ Res Public Health. 2020 Jun 19;17(12):4431. doi: 10.3390/ijerph17124431. Int J Environ Res Public Health. 2020. PMID: 32575651 Free PMC article.
-
Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study.Clin Pharmacol Ther. 2020 Nov;108(5):1055-1066. doi: 10.1002/cpt.1893. Epub 2020 Jul 2. Clin Pharmacol Ther. 2020. PMID: 32415986 Free PMC article. Clinical Trial.
-
Concentration-dependent mortality of chloroquine in overdose.Elife. 2020 Jul 8;9:e58631. doi: 10.7554/eLife.58631. Elife. 2020. PMID: 32639233 Free PMC article.
References
-
- WHO . World Malaria Report. Geneva: World Health Organization; 2014.
-
- Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101:351–359. doi: 10.1016/j.trstmh.2006.06.008. - DOI - PMC - PubMed
-
- Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, Nakavej A, Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006;11:211–219. doi: 10.1111/j.1365-3156.2005.01557.x. - DOI - PubMed
-
- Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH, Na-Bangchang K. Clinical-parasitological response and in vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans R Soc Trop Med Hyg. 2006;100:410–418. doi: 10.1016/j.trstmh.2005.04.024. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
